Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Stock-Based Compensation Expense) (Details)

v3.23.3
Stockholders' Equity (Stock-Based Compensation Expense) (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Aug. 10, 2023
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stockholders' Equity Note, Stock Split, Conversion Ratio 0.0667        
Stock-based compensation expense   $ 4,377 $ 6,837 $ 13,325 $ 17,481
Avenue Therapeutics, Inc [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock-based compensation expense   561 26 599 638
Checkpoint [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock-based compensation expense   689 781 2,225 2,285
Mustang          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock-based compensation expense   100 496 380 1,810
Journey          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock-based compensation expense   558 1,438 2,077 2,985
Other Partners [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock-based compensation expense   7 17 57 40
Employee and non-employee awards          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock-based compensation expense   2,077 2,548 6,785 7,506
Executive awards          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock-based compensation expense   $ 385 $ 1,531 $ 1,202 $ 2,217